Jan 29 (Reuters) - Median Technologies SA ALMDT.PA :
* 2023 REVENUE: EUR 22.2M, BELOW 2022 REVENUE.
* COMPANY CASH HORIZON: Q2 2025.
* ORDER BACKLOG AT ALL-TIME HIGH OF €66.9M
* ARE TARGETING FDA 510(K) CLEARANCE FOR CADE/CADX SOFTWARE
AS
MEDICAL DEVICE EYONIS™ LCS IN Q1 2025, FOLLOWED BY LAUNCH FOR US
LUNG CANCER SCREENING MARKET, WHICH COVERS 14.5 MILLION PEOPLE
WITH AN EXISTING REIMBURSEMENT PER PROCEDURE OF $650
* Q4 2023 REVENUE TOTALED €5.3M, ABOVE THE €5.1M GENERATED
IN THE
SAME PERIOD IN 2022.
* EXPECT TO RETURN TO GROWTH IN 2024 ON BACK OF A DECLINE IN
2023
REVENUE DUE TO SOFT ORDER INTAKE IN CHINA CAUSED BY COVID
LOCKDOWNS IN 2022 AND H1 2023
* 2024 STRATEGIC OUTLOOK AND KEY MILESTONES: SCALE UP THE
ICRO
CORE BUSINESS, WITH DOUBLE DIGIT GROWTH PROPELLED BY A RECOVERY
IN CHINA AND AN ACCELERATION IN US BUSINESS.
Source text for Eikon: ID:nBwCJfzMa
Further company coverage: ALMDT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))